Loxo Oncology (NASDAQ:LOXO) is scheduled to be announcing its earnings results before the market opens on Thursday, August 9th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter.
Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The firm had revenue of $38.43 million for the quarter, compared to the consensus estimate of $12.72 million. During the same quarter in the prior year, the company posted ($0.96) earnings per share. On average, analysts expect Loxo Oncology to post $1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Get Loxo Oncology alerts:
Shares of NASDAQ LOXO traded down $1.03 during midday trading on Friday, reaching $168.00. 14,738 shares of the stock traded hands, compared to its average volume of 433,500. The company has a market capitalization of $5.10 billion, a P/E ratio of -31.73 and a beta of 2.32. Loxo Oncology has a one year low of $69.83 and a one year high of $208.95.
In related news, CEO Joshua H. Bilenker sold 15,000 shares of the stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $136.51, for a total transaction of $2,047,650.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Timothy M. Mayleben sold 10,000 shares of the stock in a transaction on Friday, June 8th. The shares were sold at an average price of $179.55, for a total value of $1,795,500.00. Following the sale, the director now owns 59,732 shares in the company, valued at approximately $10,724,880.60. The disclosure for this sale can be found here. Insiders have sold a total of 1,548,678 shares of company stock worth $277,153,641 in the last 90 days. 17.10% of the stock is currently owned by insiders.
A number of research analysts have recently commented on LOXO shares. BidaskClub upgraded Loxo Oncology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 7th. Citigroup increased their target price on Loxo Oncology to $178.00 and gave the company a “buy” rating in a research report on Friday, May 18th. Morgan Stanley increased their target price on Loxo Oncology from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, June 4th. JMP Securities increased their target price on Loxo Oncology from $182.00 to $221.00 and gave the company a “buy” rating in a research report on Monday, June 4th. Finally, Zacks Investment Research downgraded Loxo Oncology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 8th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Loxo Oncology presently has an average rating of “Buy” and an average target price of $184.40.
Loxo Oncology Company Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Recommended Story: Average Daily Trade Volume – What You Need to Know